Camp4 Therapeutics Inc (CAMP)
Camp4 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies for genetic diseases. Its lead candidate, CMP-001, is being evaluated in a Phase 1/2 trial for urea cycle disorders, while CMP-002 is being developed for SYNGAP1-related disorders. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. It was previously known as Marauder Therapeutics, Inc. before adopting the Camp4 Therapeutics name in March 2018. Camp4 Therapeutics common stock trades on the NASDAQ under the symbol CAMP.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CAMP
|
$3.76
|
-11.2% Downside
|
Fair
|
$9.92
|
133.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 19, 2026
|
63.1x
|
263.6 M
|
182 M
|
0.9%
|
61.3%
|
-4.4
|
26.8%
|
